Hepatitis C: New Insights and Therapeutics by RNAi
Qiuwei Pan and Luc J.W. van der Laan
from: RNA Interference and Viruses: Current Innovations and Future Trends (Edited by: Miguel Angel Martínez). Caister Academic Press, U.K. (2010)
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis and its sequels, end-stage liver disease and hepatocellular carcinoma, are the most common indications for liver transplantation. The current standard treatment, pegylated-interferon-alpha in combination with ribavirin, represents a milestone in therapy, but only eradicates the virus in half of the patients, leaving tens of millions without hope for a cure. Therefore, it is urgent to explore novel and more effective therapeutic options. Such advancements could be derived from a better understanding of HCV biology. Progress in this area has accelerated with the application of RNA interference (RNAi) as a discovery tool to investigate viral and host cell factors involved in viral infection. Furthermore, RNAi has high potential as a therapeutic avenue for treatment of HCV. In this chapter, we aim to provide a comprehensive overview of the current developments and the potential application of RNAi in research and therapy of HCV infection read more ...